Price (delayed)
$3.5
Market cap
$670.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$638.87M
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple
There are no recent dividends present for ABUS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.